Summary
The purpose of this retrospective multicentre study was to assess the prognostic value of urokinase plasminogen activator (uPA) and p53 levels in a large series of primary breast cancer, using an automatic quantitative luminometric method. Samples of 1245 operable breast tumours were collected from seven French institutions and patients were followed for a median of 75 months. The median uPA and p53 levels assayed in cytosols by means of the immunoluminometric technique (LIA) were 0.31 and 0.20 ng mg–1 of protein respectively. In univariate analysis, high levels of uPA and p53 were associated with shorter disease-specific survival, disease-free interval, and distant recurrence-free interval. The 5-year survival rates were 95.5% among patients with uPA values below the 20th percentile, and 77.5% in those with values above the 80th percentile. The 5-year survival rates were 91.0% in patients with p53 values below the 20th percentile, and 77.6% in those with values above the 80th percentile. In multivariate analysis, the risk of disease-related death increased with uPA levels after adjustment for tumour size, histological grade, lymph node involvement, and estrogen receptor status. A high level of uPA was also related to a shorter disease-free interval and distant recurrence-free interval. In node-negative patients, a high level of uPA remained strongly related to the three outcomes. When adjusted for other prognostic factors, p53 was no longer significantly related to the outcomes. Given its rapidity and simple application to routinely prepared cytosols, this LIA may be useful for evaluating the prognostic impact of uPA in primary breast cancer, particularly in node-negative patients. According to our results, the prognostic value of p53 accumulation is limited when uPA is included in multivariate analysis.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Akaike, H. (1974). A new look at the statistical model identification. IEEE Transactions on Automatic Control 19: 716–723.
Allred, D. C., Clark, G. M., Elledge, R., Fuqua, S. A., Brown, R. W., Chamness, G. C., Osborne, C. K. & McGuire, W. L. (1993). Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200–206.
Altman, D. G. (1991). Categorising continuous variables. Br J Cancer 64: 975
Altman, D. G., Lausen, B., Sauerbrei, W. & Schumacher, M. (1994). Dangers of using ‘optimal’ cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829–835.
Andreasen, P. A., Kioller, L., Christensen, L. & Duffy, M. J. (1997). The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1–22.
Banks, L., Matlashewski, G. & Crawford, L. (1986). Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159: 529–534.
Berns, EMJJ, De Witte, H. H., Klinj, J. G. M., Willman, K., Look, M. P., Meijer-van Gelder, M. E., Benraad, T. & Foekens, J. (1997). Prognostic value of TP53 protein accumulation in human primary breast cancer: an analysis by luminometric immunoassay on 1491 tumor cytosols. Anticancer Res 17: 3003–3006.
Bloom, H. J. & Richardson, W. W. (1957). Histological grading and prognosis in breast cancer. Br J Cancer 11: 359–377.
Borg, A., Lennersand, J., Stenmark-Askmalm, M., Fernö, M., Brisfors, A., Öhrvik A Stål, O., Killander, D., Lane, D. & Brundell, J. (1995). Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer 71: 1013–1017.
Bouchet, C., Spyratos, F., Martin, P. M., Hacène, K., Gentile, A. & Oglobine, J. (1994). Prognostic value of urokinase activator and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinoma. Br J Cancer 69: 398–405.
Bouchet, C., Spyratos, F., Hacène, K., Durcos, L., Bécette, V. & Oglobine, J. (1998). Prognostic value of urokinase activator in primary breast carcinoma: comparison of two immunoassay methods. Br J Cancer 77: 1495–1501.
Cox, D. R. (1972). Regression models and life tables (with discussion). J R Stat Soc B 34: 187–202.
De Witte, H. H., Foekens, J. A., Lennerstrand, J., Smid, M., Look, M. P., Klijn, G. M., Benraad, T. J. & Berns, M. J. J. (1996). Prognostic significance of tp53 accumulation in human primary breast cancer: comparison between a rapid quantitative immunoassay and SSCP analysis. Int J Cancer 69: 125–130.
Duffy, M. J. (1996). Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613–618.
Elledge, R. M. (1996). Assessing p53 status in breast cancer prognosis; where should you put the thermometer if you think your p53 is sick? J Natl Cancer Inst 88: 141–142.
Elledge, R. M., Clark, G. M., Fuqua, S. A. W. & Yu, Y. Y. (1994). Allred C: p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 54: 3752–3757.
EORTC (European Organization for Research and Treatment of Cancer) (1980). Breast cancer cooperative group. Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 16: 1513–1515.
Falette, N., Paperin, M. p., Treilleux, I., Gratadour, A. C., Peloux, N., Mignote, H., Tooke, N., Lofman, E., Iganas, M., Brémond, A., Ozturk, M. & Puisieux, A. (1998). Prognostic value of p53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res 58: 1451–1456.
Fernö, M., Bendahl, P. O., Borg, A., Brundell, J., Hirschberg, L., Olsson, H. & Killander, D. (1996). Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with luminometric immunoassay. Eur J Cancer 5: 793–801.
Figueroa, J. A., Yee, D. & McGuire, W. L. (1993). Prognostic indicators in early breast cancer. Am J Med Sci 305: 176–182.
Foekens, J. A., Schmitt, M., Van Putten, W. L. J., Peters, H. A., Bontenbal, M., Jänicke, F. & Klijn, J. G. M. (1992). Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer. Cancer Res 52: 6101–6105.
Foekens, J. A., Schmitt, M., Van Putten, W. L. J., Peters, H. A., Kramer, M. D., Jäunicke, F. & Klijn, J. G. M. (1994). Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648–1658.
Gottlieb, T. M. & Oren, M. (1996). p53 in growth control and neoplasia. Biochem Biophys Acta 1287: 77–102.
Jänicke, F., Schmitt, M., Pache, L., Harbeck, N., Höfler, H. & Graeff, H. (1993). Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195–208.
Jänicke, F., Pache, L., Schmitt, M., Ulm, K., Thomssen, C., Prechtl, A. & Graeff, H. (1994a). Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor-type 1. Cancer Res 54: 2527–2530.
Jänicke, F., Thomssen, C., Pache, M., Schmitt, M. & Graeff, H. (1994b). Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients. In Prospects in Diagnosis and Treatment of Breast Cancer, Schmitt M, Graeff H and Kendermann G (eds) pp. 207–218. Excerpta Medica: Amsterdam
Kaplan, E. L. & Meier, P. (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481.
Knoop, A., Andreasen, P. A., Andreasen, J. A., Hansen, S., Laenkholm, A. V., Simonsen, A. C. W., Andersen, J., Overgaard, J. & Rose, C. (1998). Prognostic significance of urokinase-type plasminogen activator and type plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 77: 932–940.
MacGrogan, G., Bonichon, F., de Mascarel, I., Trojani, M., Durand, M., Avril, A. & Coindre, J. M. (1995). Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study of 942 cases. Breast Cancer Res Treat 36: 71–81.
Mantel, N. (1966). Evaluation of survival data and two rank order statistics arising in its consideration. Cancer Chemother Res 50: 163–170.
Peyrat, J. P., Vanlemmens, L., Fournier, J., Huet, G., Révillon, F. & Bonneterre, J. (1998). Prognostic value of p53 and urokinase-type plasminogen activator in node negative human breats cancers. Clin Cancer Res 4: 189–196.
Pichon, M. F., Broët, P., Magdelenat, H., Delarue, J. C., Spyratos, F., Basuyau, J. P., Saez, S., Rallet, A., Courrière, R., Millon, R. & Asselain, B. (1996). Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancer. Br J Cancer 73: 1545–1552.
Porter-Jordan, K. & Lippman, M. E. (1994). Overview of the biologic markers of breast cancer. Hematol Oncol Clin North Am 8: 73–100.
Scarff, R. W. & Torloni, H. (1968). Histological Typing of Breast Tumors, pp. 13–20. World Health Organization: Geneva 13–20
Schmitt, M., Thomssen, C., Ulm, K., Selderer, A., Harbeck, N., Höfler, H., Jänicke, F. & Graeff, H. (1997). Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer. Br J Cancer 76: 306–311.
Sjörgren, S., Iganas, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L. & Bergh, J. (1996). The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88: 173–182.
S-Plus Version 3.2 Guide to Statistics (1993). Statistical Sciences, Seattle, WA
Therneau, T. M., Grambsch, P. M. & Fleming, T. R. (1990). Martingale-based residuals for survival models. Biometrika 77: 147–160.
Thor, A. D. & Yandell, D. W. (1993). Prognostic significance of p53 overexpression in node-negative breast carcinomas: preliminary results support cautious optimism. J Natl Cancer Inst 85: 176–177.
UICC (Union Internationale Contre le Cancer). (1988) TNM Classification des Tumeurs Malignes, Springer-Verlag: Paris pp. 99–106.
Velculescu, V. E. & El-Deiry, W. S. (1996). Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 42: 858–868.
Vojtesek, B., Bártek, J., Migdley, C. A. & Lane, D. P. (1992). An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immuno Methods 151: 237–244.
Author information
Authors and Affiliations
Additional information
The participating laboratories are members of the Groupe de Biopathologie Tissulaire et Moléculaire of the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Broët, P., Spyratos, F., Romain, S. et al. Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study. Br J Cancer 80, 536–545 (1999). https://doi.org/10.1038/sj.bjc.6690389
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690389
Keywords
This article is cited by
-
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies
Breast Cancer Research (2014)
-
Relations du système plasminogène-plasmine et cancer
Oncologie (2010)
-
Prognostic molecular markers in early breast cancer
Breast Cancer Research (2004)